Cancer Research UK’s Centre for Drug Development (CDD) has entered into a collaboration with TrialAssure to evaluate artificial intelligence-assisted regulatory document authoring, supporting medical writing teams as oncology research programmes continue to increase in complexity.
The initiative will see the Centre for Drug Development assess TrialAssure LINK AI across a range of regulatory and clinical documentation workflows while maintaining experienced medical writers at the centre of the review, refinement and approval process.
The organisations say the collaboration aims to improve efficiency, reduce repetitive administrative tasks and support the continued expansion of Cancer Research UK’s clinical development portfolio.
Supporting regulatory document authoring
Cancer Research UK’s Centre for Drug Development began evaluating LINK AI for regulatory document authoring by assessing its use within Investigator’s Brochure workflows.
Working alongside TrialAssure, the organisation adapted the platform’s artificial intelligence capabilities to align with existing templates and internal authoring guidance before reviewing AI-generated drafts using a structured human-in-the-loop process.
Following the initial assessment, Cancer Research UK plans to extend the evaluation into additional regulatory document types including Clinical Study Reports and patient narratives.
Growing demand for efficient clinical development
As oncology research programmes continue to expand, regulatory documentation requirements have become increasingly complex.
Modern clinical studies frequently involve combination therapies, precision medicine approaches and multinational regulatory submissions, creating greater demand for accurate, consistent and timely medical writing.
Artificial intelligence is increasingly being explored across the pharmaceutical sector as a tool to assist with structured content generation while maintaining expert human oversight throughout regulated development processes.
Human expertise remains central
According to the organisations, the collaboration is designed to augment rather than replace experienced medical writers.
The AI platform supports initial content generation, while regulatory specialists remain responsible for scientific review, quality assurance and document finalisation.
Responsible AI adoption in life sciences
The collaboration reflects a wider trend across the pharmaceutical industry as organisations explore practical applications of generative artificial intelligence within highly regulated environments.
By combining AI-assisted drafting with expert review, organisations aim to improve operational efficiency while maintaining scientific accuracy, regulatory compliance and patient safety.
Cancer Research UK’s Centre for Drug Development said the phased implementation provides a structured framework for evaluating AI within existing regulatory authoring workflows as the organisation continues to develop new oncology treatments. :contentReference[oaicite:3]{index=3}
Frequently Asked Questions
What is TrialAssure LINK AI?
LINK AI is an artificial intelligence platform designed to assist with the preparation of clinical and regulatory documentation while supporting expert medical writers.
Who is involved in the collaboration?
The collaboration involves TrialAssure and Cancer Research UK’s Centre for Drug Development.
What documents are being evaluated?
The initial assessment focuses on Investigator’s Brochures before expanding into Clinical Study Reports and patient narratives.
Will AI replace medical writers?
No. According to both organisations, experienced medical writers remain responsible for reviewing, refining and approving all regulatory documents.
Where can I find more information?
Further information is available from TrialAssure LINK AI and Cancer Research UK’s Centre for Drug Development.
